Last reviewed · How we verify

NCT06382779

Proximal Humerus Reconstruction After Resection for Tumors : Comparison Between Allograft Prosthetic Composite and Cement Sleeve Prosthetic Composite

ENROLLING BY INVITATION Last updated 24 April 2024
What this trial tests

trial testing reverse shoulder arthroplasty in Shoulder Disease in 32 participants. Enrolling by invitation.

Timeline
15 April 2024
Primary endpoint
1 May 2024
1 May 2024

Quick facts

Lead sponsorCentral Hospital, Nancy, France
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment32
Start date15 April 2024
Primary completion1 May 2024
Estimated completion1 May 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, any sex, with Shoulder Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Proximal humerus is a common site for primary bone tumors and metastatic disease. Reconstruction with reverse shoulder arthroplasty (RSA) after resection is a surgical challenge and presented high risk of complication. The options for reconstruction after proximal humerus tumor resection are limited, and depend on the soft tissue conditions and bone loss. The most commonly used techniques include long cemented stem alone (in case of limited resection), allograft prosthetic composite (APC), massive prosthesis. In some cases two step procedure are performed : first step is resection and RSA with cement sleeve, and second step is APC or massive prosthesis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of reverse shoulder arthroplasty

Trials testing the same drug.

Other recruiting trials for Shoulder Disease

Currently open trials in the same condition.

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06382779.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing